Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
暂无分享,去创建一个
Molly Brewer | Beth Y Karlan | Daniela Matei | D. Matei | B. Karlan | J. Hainsworth | T. Pham | D. Eberhard | U. Matulonis | C. Aghajanian | G. Fleming | M. Pegram | R. Schilder | L. Roman | M. Brewer | M. Gordon | D. Cohn | M. Derynck | D. Allison | K. Ng | Ursula A Matulonis | Russell J Schilder | Gini F Fleming | Carol Aghajanian | John D Hainsworth | David A Eberhard | David E Cohn | Mark D Pegram | Michael S Gordon | Agustin A. Garcia | Kimmie Ng | Agustin A Garcia | Mika K Derynck | Benjamin Lyons | David E Allison | Lynda Roman | Thinh Q Pham | Randall C Dere | B. Lyons | Thinh Q. Pham
[1] L. Presta,et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab , 2006, Cancer Immunology, Immunotherapy.
[2] R. Edwards,et al. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study , 2004, International Journal of Gynecologic Cancer.
[3] Lesley Seymour,et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. , 2005, The New England journal of medicine.
[4] J. Doroshow. Targeting EGFR in non-small-cell lung cancer. , 2005, The New England journal of medicine.
[5] M. Gonen,et al. Randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer , 2005 .
[6] W. Voigt,et al. Cetuximab with oxaliplatin and capecitabine (CAPOX)in patients with metastatic colorectal cancer (mCRC) refractory to standard chemotherapy , 2005 .
[7] Daohai Yu,et al. A phase II study of oxaliplatin, capecitabine and bevacizumab in the treatment of metastatic colorectal cancer , 2005 .
[8] Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer , 2005 .
[9] F. Penault-Llorca,et al. HER2 overexpression and amplification in advanced ovarian cancer (OC): Preliminary results from a large GINECO study , 2005 .
[10] S. Dakhil,et al. Cetuximab + FOLFOX 6 as first line therapy for metastatic colorectal cancer , 2005 .
[11] J. Hainsworth,et al. Safety and efficacy of bevacizumab (Bev) when added to oxaliplatin/fluoropyrimidine (O/F) regimens as first-line treatment of metastatic colorectal cancer (mCRC): TREE 1 & 2 Studies , 2005 .
[12] R. Gray,et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial - E4599 , 2005 .
[13] B. Karlan,et al. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P Kelly Marcom,et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] A. Jemal,et al. Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.
[16] M. Sliwkowski,et al. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. , 2004, Cancer cell.
[17] Daniel Normolle,et al. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Rustin,et al. Use of CA-125 to assess response to new agents in ovarian cancer trials. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] M. Sliwkowski,et al. Dose-response studies of recombinant humanized monoclonal antibody 2C4 in tumor xenograft models , 2003 .
[20] Michael Kofler,et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. , 2003, Molecular cell.
[21] K. Darcy,et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] D. Armstrong. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. , 2002, The oncologist.
[23] Brian Higgins,et al. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. , 2002, Cancer cell.
[24] D Guthrie,et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.
[26] M. van Glabbeke,et al. New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.
[27] G. Mills,et al. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] M. Campiglio,et al. Characteristics of EGFR family‐mediated HRG signals in human ovarian cancer , 1999, Journal of cellular biochemistry.
[29] K L King,et al. Biological response to ErbB ligands in nontransformed cell lines correlates with a specific pattern of receptor expression. , 1998, Endocrinology.
[30] R. Bast,et al. Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. , 1998, Hybridoma.
[31] N. Hynes,et al. ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling , 1997, The EMBO journal.
[32] Y. Yarden,et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor , 1996, Molecular and cellular biology.
[33] P. Sismondi,et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. , 1996, British Journal of Cancer.
[34] R. Bast,et al. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian cancer. , 1990, Cancer research.
[35] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.